These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17106785)

  • 21. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
    Emkey R
    MedGenMed; 2004 Jul; 6(3):6. PubMed ID: 15520628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
    Guerra-García MM; Rodríguez-Fernández JB; Puga-Sarmiento E; Charle-Crespo MÁ; Gomes-Carvalho CS; Prejigueiro-Santás A
    Aten Primaria; 2011 Feb; 43(2):82-8. PubMed ID: 20554353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
    Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Silvestri S; Agnusdei D; Gentilella R; Nuti R;
    Osteoporos Int; 2008 Aug; 19(8):1219-23. PubMed ID: 18286217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
    Osaki M; Tatsuki K; Hashikawa T; Norimatsu T; Chiba K; Motokawa S; Furuichi I; Doiguchi Y; Aoyagi K; Shindo H
    Osteoporos Int; 2012 Feb; 23(2):695-703. PubMed ID: 21394496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
    Hodsman AB; Hanley DA; Josse R
    CMAJ; 2002 May; 166(11):1426-30. PubMed ID: 12054412
    [No Abstract]   [Full Text] [Related]  

  • 31. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
    Masud T; McClung M; Geusens P
    Clin Interv Aging; 2009; 4():445-9. PubMed ID: 19966913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
    Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
    Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
    Compston JE
    Bone; 2000 Dec; 27(6):765-8. PubMed ID: 11113386
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.